Oxygen Biotherapeutics announces fiscal year 2014 financial results
Oxygen Biotherapeutics reported a net loss of $19.5 million or $2.71 per share for the fiscal year 2014, compared to a net loss of $9.4 million, or $6.29 per share in the prior year. In FY 2014, the Company recognized $263,000 in grant revenue, compared to $1.1 million in the prior year. July 29, 2014